Atria Investments Inc Sells 1,568 Shares of CME Group Inc. $CME

01 Nov 2025, 08:02 by Doug Wharley · The Cerbat Gem

Atria Investments Inc lessened its holdings in CME Group Inc. (NASDAQ:CME – Free Report) by 5.3% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 27,923 shares of the financial services provider’s stock after selling 1,568 shares during the period. Atria Investments Inc’s holdings in CME Group were worth $7,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Savvy Advisors Inc. bought a new stake in CME Group in the 2nd quarter valued at $332,000. Assetmark Inc. increased its holdings in CME Group by 36.1% in the 2nd quarter. Assetmark Inc. now owns 34,144 shares of the financial services provider’s stock valued at $9,411,000 after buying an additional 9,063 shares during the period. HBK Sorce Advisory LLC increased its holdings in CME Group by 38.9% in the 2nd quarter. HBK Sorce Advisory LLC now owns 1,190 shares of the financial services provider’s stock valued at $328,000 after buying an additional 333 shares during the period. Premier Path Wealth Partners LLC increased its holdings in CME Group by 8.7% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 1,616 shares of the financial services provider’s stock valued at $445,000 after buying an additional 129 shares during the period. Finally, Hantz Financial Services Inc. grew its holdings in shares of CME Group by 83.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 329 shares of the financial services provider’s stock worth $91,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 87.75% of the company’s stock.

CME Group Stock Up 1.0%

Shares of NASDAQ:CME opened at $265.49 on Friday. CME Group Inc. has a 12 month low of $213.94 and a 12 month high of $290.79. The company’s 50-day moving average price is $265.83 and its two-hundred day moving average price is $272.03. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The firm has a market cap of $95.68 billion, a P/E ratio of 25.73, a P/E/G ratio of 4.41 and a beta of 0.41.

CME Group (NASDAQ:CME – Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The financial services provider reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.05. CME Group had a net margin of 58.84% and a return on equity of 14.61%. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the firm earned $2.68 EPS. The company’s revenue was down 3.0% on a year-over-year basis. As a group, research analysts forecast that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 25th. Shareholders of record on Tuesday, September 9th were issued a dividend of $1.25 per share. The ex-dividend date of this dividend was Tuesday, September 9th. This represents a $5.00 dividend on an annualized basis and a yield of 1.9%. CME Group’s dividend payout ratio is currently 48.45%.

Insider Activity at CME Group

In other CME Group news, insider Sunil Cutinho sold 11,896 shares of the company’s stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $271.47, for a total transaction of $3,229,407.12. Following the transaction, the insider directly owned 17,440 shares in the company, valued at approximately $4,734,436.80. This represents a 40.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William R. Shepard bought 262 shares of the business’s stock in a transaction on Thursday, September 25th. The shares were acquired at an average price of $265.19 per share, for a total transaction of $69,479.78. Following the completion of the transaction, the director owned 258,459 shares in the company, valued at approximately $68,540,742.21. This trade represents a 0.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 13,043 shares of company stock worth $3,527,956 in the last quarter. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CME. Morgan Stanley upped their target price on shares of CME Group from $312.00 to $314.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. JPMorgan Chase & Co. upped their target price on shares of CME Group from $252.00 to $256.00 and gave the stock an “underweight” rating in a report on Tuesday, October 14th. Keefe, Bruyette & Woods upped their target price on shares of CME Group from $283.00 to $287.00 and gave the stock a “market perform” rating in a report on Monday, October 13th. Piper Sandler upped their target price on shares of CME Group from $283.00 to $296.00 and gave the stock an “overweight” rating in a report on Tuesday, July 15th. Finally, Oppenheimer upped their target price on shares of CME Group from $300.00 to $303.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $284.53.

View Our Latest Stock Analysis on CME Group

CME Group Company Profile

(Free Report)